Fox (Michael J.) Foundation for Parkinson's Research

14-3-3 Phosphorylation as a Biomarker for Parkinson's Disease

14-3-3 Phosphorylation as a Biomarker for Parkinson's Disease

14-3-3s as Regulators of LRRK2 Toxicity

A Diffusion Tensor Based Biomarker for Parkinson's Disease

ASAP PFF Support and Characterization

Advancing Biological Understanding of PINK1 and Parkin Mouse and Rat Models of PD

Advancing PINK1 KO Rat Animal Models of PD

Advancing PINK1 KO Rat Animal Models of PD

Alpha-Galactosidase A and Glycosphingolipid Metabolites as Putative Biomarkers for PD

Alpha-Galactosidase A as a Therapeutic Target for Parkinson's Disease

Analysis of Parkin Activity in W403A Parkin Knockin Mice

Characterization of the in Vivo Effects of aSyn PFFs on Mouse Brain Mitochondria

Clinician-Input Study: How the Fox Insight Mobile Application can Influence Treatment and Care (CIS-PD)

Clinician-input Study: How the Fox Wearable Companion Mobile Application can Influence Treatment and Care (CIS-PD)

Cytokine Production by Adaptive Immune Cells from Patients with Parkinson’s Disease: Response to Diverse Biological Stimuli

DWI and Olfaction as PD a Biomarker

Defining Alpha-Synuclein Conformers Responsible for PD Phenotypes in Mice

Determining PINK1 and PRKN Enzyme Activities in Vivo

Efficacy of Parkin Gene Delivery Towards Mitigation of A-Syn PFF-Induced Degeneration

Efficacy of Parkin Gene Delivery Towards Mitigation of aSyn PFF-induced Degeneration

Elucidating Cell Type-Specific PINK1 and PRKN Expression in Vivo

Expansion Microscopy to Visualize Intracellular aSyn Pathology

Fox Investigation for New Discovery of Biomarkers (BioFIND)

Global Parkinson's Genetics Program Clinical Contribution Agreement

Identification and Rescue of Striatal Circuit Abnormalities in Models of GNAL Dystonia

Identification of Robust and Relevant Pre-Clinical Phenotypes for LRRK2 Therapeutics

Immune Cell Dysfunction in PINK1 PD Animal Models

Investigating the Phenotype of B-Cells in Peripheral Blood of PD Patients

MJFF Emerging Targets Committee Membership

MOU - LRRK2 Consortium Memorandum of Understanding

Mechanisms of LRRK2 Membrane Association

Parkinson Disease Genetics in the Black American Population

Seeking Neuro-Protection Via a Novel Complex-1 Chaperone Supplement

Targeting MHCII Proteins on CNS Resident Microglia in an Alpha-Synuclein Model of Parkinson Disease

Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease

Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease

The Edmond J. Safra Fellowship in Movement Disorders

The Edmond J. Safra Fellowship in Movement Disorders 2019 Program

The Parkinson's Progression Marker's Initiative (PPMI)

The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical - Establishing a Deeply Phenotyped PD Cohort

The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical - Establishing a Deeply Phenotyped PD Cohort

The Role of the JAK/STAT Pathway in Human Parkinson's Disease

The Systemic Synuclein Sampling Study (S4)

Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease

Unfolded Protein Response (UPR) Perk Signaling in Parkinson's Disease Progression

University of Alabama at Birmingham_The Edumond J. Safra Fellowship in Movement Disorders 2017

Unlocking Dystonia from Parkinson's Disease with Directional DBS Technology

Utilizing Transcriptional Pathways to Enhance Mitochondrial Health in Models of PD

Validate PFF a-syn-induced Inflammatory Phenotype in Mice

Validation of CCR2-Dependent Monocyte Entry in Alpha-Synuclein-Induced Toxicity

Validation of CCR2-Dependent Monocyte Entry in Alpha-Synuclein-lnduced Toxicity

Validation of CD4 T cell Dependent Neurotoxicity in an Alpha-synuclein Model of PD

Validation of Dyskinesis Rating Scales

Validation of the Class II MHC Transactivator (CIITA) in Models of PD